Hepatitis C virus inhibitors and uses thereof in preparation of drugs

Patent metadata

Field	Value
Publication number	US-10160771-B2
Application number	US-201515516293-A
Country	US
Kind code	B2
Filing date	Feb 6, 2015
Priority date	Feb 21, 2014
Publication date	Dec 25, 2018
Grant date	Dec 25, 2018

Abstract

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

First claim

What is claimed is:

1. A compound represented by formula (V) or a pharmaceutically acceptable salt thereof,

wherein,
D 1 D 7 are each independently selected from

D 2 D 6 are each independently selected from

D 5 is selected from a single bond,

the structure unit

 is selected from

D 4 is selected from

optionally, the compound or the pharmaceutically acceptable salt thereof contains one or multiple chiral centers.

2. The compound according to claim 1 , which includes:

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, D 2 , D 6 are each independently selected from

4. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, D 2 , D 6 are each independently selected from

5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, D 1 , D 7 are each independently selected from

6. A pharmaceutical composition, which comprises a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier.

7. A process for treating HCV in a subject in need thereof, comprising administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 or the pharmaceutical composition according to claim 6 to the subject.

Assignees

• Changzhou Yinsheng Pharmaceutical Co Ltd
• Univ Sichuan

Inventors

• Zhang Yang
• Shen Chunli
• Li Jian
• Chen Shuhui
• Hu Guoping
• Wei Yuquan
• Yu Luoting
• Tao Xin

Classifications

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title

• A61K31/4184

  condensed with carbocyclic rings, e.g. benzimidazoles · CPC title